Teva Pharmaceutical Industries Limited (TEVA)
USD 21.2
(1.53%)
USD 21.2
(1.53%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.84 Billion | 14.92 Billion | 15.87 Billion | 16.65 Billion | 16.88 Billion | 18.85 Billion |
| Cost of Revenue | 8.2 Billion | 7.95 Billion | 8.28 Billion | 8.93 Billion | 9.35 Billion | 10.55 Billion |
| Gross Profit | 7.64 Billion | 6.97 Billion | 7.59 Billion | 7.72 Billion | 7.53 Billion | 8.29 Billion |
| Operating Expenses | 4.45 Billion | 4.28 Billion | 4.49 Billion | 4.66 Billion | 4.81 Billion | 5.42 Billion |
| Selling, General and Administrative Expenses | 3.49 Billion | 3.44 Billion | 3.52 Billion | 3.67 Billion | 3.8 Billion | 4.21 Billion |
| Research and Development Expenses | 953 Million | 838 Million | 967 Million | 997 Million | 1.01 Billion | 1.21 Billion |
| Other Expenses | - | 107 Million | 98 Million | -4 Million | 76 Million | 291 Million |
| Cost and Expenses | 15.41 Billion | 12.23 Billion | 12.77 Billion | 13.6 Billion | 14.16 Billion | 15.98 Billion |
| Operating Income | 433 Million | 2.79 Billion | 3.19 Billion | 3.05 Billion | 2.79 Billion | -1.63 Billion |
| Interest Expense | 1.02 Billion | 966 Million | 1.05 Billion | 963 Million | 822 Million | 881 Million |
| Income Tax Expense | -7 Million | -638 Million | 211 Million | -168 Million | -278 Million | -195 Million |
| Earnings before Tax | -624 Million | -3.06 Billion | 658 Million | -4.4 Billion | -1.26 Billion | -2.59 Billion |
| Net Income | -559 Million | -2.35 Billion | 417 Million | -3.99 Billion | -999 Million | -2.15 Billion |
| Earnings Per Share Basic | -0.50 | -2.12 | 0.38 | -3.64 | -0.92 | -2.11 |
| Earnings Per Share Diluted | -0.50 | -2.12 | 0.38 | -3.64 | -0.92 | -2.11 |
| Weighted Average Shares Outstanding | 1.11 Billion | 1.11 Billion | 1.1 Billion | 1.09 Billion | 1.09 Billion | 1.02 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.11 Billion | 1.11 Billion | 1.1 Billion | 1.09 Billion | 1.09 Billion | 1.02 Billion |
| Gross Margin | 0.48 | 0.47 | 0.48 | 0.46 | 0.45 | 0.44 |
| EBIT Margin | 0.27 | 0.28 | 0.29 | 0.28 | 0.19 | 0.17 |
| Profit Margin | -0.04 | -0.16 | 0.03 | -0.24 | -0.06 | -0.11 |
| EBITDA | 4.33 Billion | -874 Million | 4.4 Billion | -2.09 Billion | 1.27 Billion | 186 Million |
| Earnings Before Tax Margin | 0.03 | 0.19 | 0.20 | 0.18 | 0.17 | -0.09 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 4.16 Billion | 3.83 Billion | 15.84 Billion | 4.45 Billion | 3.85 Billion | 3.87 Billion |
| Cost of Revenue | 2.14 Billion | 2.04 Billion | 8.2 Billion | 2.04 Billion | 1.99 Billion | 2.08 Billion |
| Gross Profit | 2.02 Billion | 1.78 Billion | 7.64 Billion | 2.41 Billion | 1.85 Billion | 1.79 Billion |
| Operating Expenses | 1.2 Billion | 1.12 Billion | 4.45 Billion | 1.12 Billion | 1.09 Billion | 1.15 Billion |
| Selling, General and Administrative Expenses | 939 Million | 886 Million | - | 902 Million | 844 Million | 910 Million |
| Research and Development Expenses | 269 Million | 242 Million | - | 227 Million | 253 Million | 240 Million |
| Other Expenses | 1 Million | 18 Million | -14 Million | -36 Million | 9 Million | 33 Million |
| Cost and Expenses | 3.34 Billion | 3.17 Billion | 12.65 Billion | 3.17 Billion | 3.09 Billion | 3.23 Billion |
| Operating Income | 814 Million | 656 Million | 433 Million | 722 Million | 355 Million | -646 Million |
| Interest Expense | 241 Million | 250 Million | 1.02 Billion | 221 Million | 280 Million | 268 Million |
| Income Tax Expense | 630 Million | -52 Million | -7 Million | 41 Million | -12 Million | -16 Million |
| Earnings before Tax | -246 Million | -467 Million | -624 Million | 473 Million | 75 Million | -914 Million |
| Net Income | -845 Million | -139 Million | -559 Million | 429 Million | 80 Million | -863 Million |
| Earnings Per Share Basic | -0.75 | -0.12 | - | 0.41 | 0.07 | -0.77 |
| Earnings Per Share Diluted | -0.75 | -0.12 | - | 0.41 | 0.07 | -0.77 |
| Weighted Average Shares Outstanding | 1.13 Billion | 1.12 Billion | 1.11 Billion | 1.12 Billion | 1.12 Billion | 1.12 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.13 Billion | 1.12 Billion | 1.11 Billion | 1.13 Billion | 1.13 Billion | 1.12 Billion |
| Gross Margin | 0.49 | 0.47 | 0.48 | 0.54 | 0.48 | 0.46 |
| EBIT Margin | 0.26 | 0.24 | - | 0.33 | 0.27 | 0.25 |
| Profit Margin | -0.20 | -0.04 | -0.04 | 0.10 | 0.02 | -0.22 |
| EBITDA | 1.07 Billion | 928 Million | - | 1.45 Billion | 1.04 Billion | 979 Million |
| Earnings Before Tax Margin | 0.20 | 0.17 | 0.03 | 0.16 | 0.09 | -0.17 |
GBIM
NDBKY
UNICHEMLAB
LHFG
600803
NIRAJ